01.02.2013 - With a €50m acquisition Novozymes puts a foot in the pulp & paper, textile, grain-processing and animal feed industries
On January 31st, the Danish enzyme specialist annouced that it will acquire the industrial enzyme business of Canadian cellulosic ethanol specialist Iogen Corporation for €50m. Earn-out payments of up to additional €10m could add to the sum. With the deal Novozymes bags the entire product portfolio of Iogen Bio-Products, including products in development, production sites and IP.
Iogen Bio-Products produces fibre modifying enzymes, such as pulp bleaching enzymes for the pulp and paper branch, fibre processing biocatalysts for textile sector, cellulases and hemicellulases fort he grain-processing and enzymes fort he animal feed industries. Closing of the take-over is expected in February 2013. With the deal Novozymes strenghtens its market position in industrial biotech which complements its already strong position in the cellulosic bioethanol segment that is expanded with aquisitions and collaborations.
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.